Burzynski Research (BZYR) 0.0700 $BZYR
Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global
Global Low-Grade Astrocytoma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d46hw6/lowgrade) has announced the addition of the "Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Low-Grade Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Burzynski Research Institute, Inc. - National Cancer Institute - City of Hope National Medical Center - Memorial Sloan Kettering Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Children's Oncology Group - New York University School of Medicine - Roswell Park Cancer Institute For more information visit http://www.researchandmarkets.com/research/d46hw6/lowgrade
Global Ependymoma Clinical Trials Review Report - H2 2013 Edition
M2 - Mon Jan 13, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rrpdm/ependymoma_global) has announced the addition of the "Ependymoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Ependymoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ependymoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Ependymoma Therapeutics Clinical Trials - Advantagene, Inc. - Astellas US Holding, Inc. - Burzynski Research Institute, Inc. - DNAtrix, Inc. - Direct Therapeutics, Inc. - Eli Lilly and Company Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - St. Jude Children's Research Hospital, Inc. - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - City of Hope National Medical Center - Children's Cancer and Leukaemia Group - Massachusetts General Hospital - Northwestern University - Cancer Research UK - Memorial Sloan Kettering Cancer Center For more information visit http://www.researchandmarkets.com/research/9r...oma_global
Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress
Business Wire - Fri Nov 15, 8:33PM CST
The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.
Astrocytoma Global Clinical Trials Review, H2, 2012
M2 - Fri Jan 18, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnsfxh/astrocytoma) has announced the addition of GlobalData's new report "Astrocytoma Global Clinical Trials Review, H2, 2012" to their offering. Astrocytoma Global Clinical Trials Review, H2, 2012" provides data on the Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in
Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global
Global Low-Grade Astrocytoma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d46hw6/lowgrade) has announced the addition of the "Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Low-Grade Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Burzynski Research Institute, Inc. - National Cancer Institute - City of Hope National Medical Center - Memorial Sloan Kettering Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Children's Oncology Group - New York University School of Medicine - Roswell Park Cancer Institute For more information visit http://www.researchandmarkets.com/research/d46hw6/lowgrade
Global Ependymoma Clinical Trials Review Report - H2 2013 Edition
M2 - Mon Jan 13, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rrpdm/ependymoma_global) has announced the addition of the "Ependymoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Ependymoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ependymoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Ependymoma Therapeutics Clinical Trials - Advantagene, Inc. - Astellas US Holding, Inc. - Burzynski Research Institute, Inc. - DNAtrix, Inc. - Direct Therapeutics, Inc. - Eli Lilly and Company Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - St. Jude Children's Research Hospital, Inc. - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - City of Hope National Medical Center - Children's Cancer and Leukaemia Group - Massachusetts General Hospital - Northwestern University - Cancer Research UK - Memorial Sloan Kettering Cancer Center For more information visit http://www.researchandmarkets.com/research/9r...oma_global
Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress
Business Wire - Fri Nov 15, 8:33PM CST
The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.
Astrocytoma Global Clinical Trials Review, H2, 2012
M2 - Fri Jan 18, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnsfxh/astrocytoma) has announced the addition of GlobalData's new report "Astrocytoma Global Clinical Trials Review, H2, 2012" to their offering. Astrocytoma Global Clinical Trials Review, H2, 2012" provides data on the Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in
